Viridian Therapeutics, Inc.\DE (VRDN) Consolidated Net Income (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Consolidated Net Income of -$111.8 million for Q1 2026, down 18.69% year-over-year from -$137.4 million in Q1 2025, and down 12.54% quarter-over-quarter from -$99.3 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Consolidated Net Income (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Consolidated Net Income history runs 14 years deep, the most recent figure standing at -$111.8 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 18.69% year-over-year to -$111.8 million; the TTM figure through Mar 2026 stood at -$357.8 million (down 5.95% YoY), while the FY2025 annual figure was -$652.8 million, down 37.16% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$111.8 million, down from -$99.3 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$25.7 million in Q1 2022, with the low at -$111.8 million in Q1 2026.
- The 5-year median for Consolidated Net Income is -$68.2 million (2023), against an average of -$66.9 million.
- The sharpest annual moves came in 2023 and 2025: Consolidated Net Income tumbled 165.39% in 2023, then surged 61.69% in 2025.
- Viridian Therapeutics, Inc.\DE's Consolidated Net Income stood at -$45.6 million in 2022, then slumped by 84.56% to -$84.2 million in 2023, then advanced by 6.04% to -$79.1 million in 2024, then declined by 25.56% to -$99.3 million in 2025, then dropped by 12.54% to -$111.8 million in 2026.
- Business Quant data shows VRDN's Consolidated Net Income at -$111.8 million in Q1 2026, -$99.3 million in Q4 2025, and -$35.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -160.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -160.80 Mn |
| Mar 31, 2026 | -111.76 Mn |
| Dec 31, 2025 | -99.31 Mn |
| Sep 30, 2025 | -35.05 Mn |
| Jun 30, 2025 | -111.67 Mn |
| Mar 31, 2025 | -94.16 Mn |
| Dec 31, 2024 | -79.09 Mn |
| Sep 30, 2024 | -91.49 Mn |
| Jun 30, 2024 | -72.96 Mn |
| Mar 31, 2024 | -57.69 Mn |
| Dec 31, 2023 | -84.18 Mn |
| Sep 30, 2023 | -47.66 Mn |
| Jun 30, 2023 | -55.06 Mn |
| Mar 31, 2023 | -68.19 Mn |
| Dec 31, 2022 | -45.61 Mn |
| Sep 30, 2022 | -28.94 Mn |
| Jun 30, 2022 | -29.54 Mn |
| Mar 31, 2022 | -25.69 Mn |
| Dec 31, 2021 | -29.14 Mn |
| Sep 30, 2021 | -14.04 Mn |